Skip to main content
. 2020 Dec 18;218(1):e20192179. doi: 10.1084/jem.20192179

Figure 1.

Figure 1.

There are several possible mechanisms contributing to irAEs in response to ICB. Importantly, these may occur distal to the tumor, in the periphery, or within the TME. It is still unclear which mechanism, if any, is the main driver of irAEs or to what degree interplay of these mechanisms contributes to disease. As irAEs are a critical limitation to cancer immunotherapy, understanding these mechanisms and how to prevent them is essential to the future of cancer immunotherapeutics.